Dexamethasone and Doxycycline Doped Nanoparticles Increase the Differentiation Potential of Human Bone Marrow Stem Cells
Authors:
Open Access
- 4 September 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (9) , 1865
Abstract
Non-resorbable polymeric nanoparticles (NPs) are proposed as an adjunctive treatment for bone regenerative strategies. The present in vitro investigation aimed to evaluate the effect of the different prototypes of bioactive NPs loaded with zinc (Zn-NPs), doxycycline (Dox-NPs) or dexamethasone (Dex-NPs) on the viability, morphology, migration, adhesion, osteoblastic differentiation, and mineralization potential of human bone marrow stem cells (hBMMSCs). Cell viability, proliferation, and differentiation were assessed using a resaruzin-based assay, cell cycle analysis, cell migration evaluation, cell cytoskeleton staining analysis, Alizarin Red S staining, and expression of the osteogenic-related genes by a real-time quantitative polymerase chain reaction (RT-qPCR). One-Way ANOVA and Tukey’s test were employed. The resazurin assay showed adequate cell viability considering all concentrations and types of NPs at 24, 48, and 72 h of culture. The cell cycle analysis revealed a regular cell cycle profile at 0.1, 1, and 10 µg/mL, whereas 100 µg/mL produced an arrest of cells in the S phase. Cells cultured with 0.1 and 1 µg/mL NP concentrations showed a similar migration capacity to the untreated group. After 21 days, mineralization was increased by all the NPs prototypes. Dox-NPs and Dex-NPs produced a generalized up-regulation of the osteogenic-related genes. Dex-NPs and Dox-NPs exhibited excellent osteogenic potential and promoted hBMMSC differentiation. Future investigations, both in vitro and in vivo, are required to confirm the suitability of these NPs for their clinical application.Keywords
Funding Information
- Ministry of Economy and Competitiveness (PID2020-114694RB-I00, PID2020-115887GB-I00, FPU20/00450)
- FPU fellowship from the Ministry of Universities (PID2020-114694RB-I00, PID2020-115887GB-I00, FPU20/00450)
- European Social Fund (ESF) (PID2020-114694RB-I00, PID2020-115887GB-I00, FPU20/00450)
- Generalitat Valenciana (PID2020-114694RB-I00, PID2020-115887GB-I00, FPU20/00450)
This publication has 49 references indexed in Scilit:
- Current views on calcium phosphate osteogenicity and the translation into effective bone regeneration strategiesActa Biomaterialia, 2012
- Electrospun Poly(L-Lactic Acid) Nanofibres Loaded with Dexamethasone to Induce Osteogenic Differentiation of Human Mesenchymal Stem CellsJournal of Biomaterials Science, Polymer Edition, 2012
- Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M SignalingStem Cells, 2012
- Proliferation, differentiation and gene expression of osteoblasts in boron-containing associated with dexamethasone deliver from mesoporous bioactive glass scaffoldsBiomaterials, 2011
- Extracellular calcium as an integrator of tissue functionThe International Journal of Biochemistry & Cell Biology, 2008
- Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cellsArchives of Oral Biology, 2007
- Collagen as a carrier for on-site delivery of antibacterial drugsAdvanced Drug Delivery Reviews, 2003
- Reduction in Transforming Growth Factor β Receptor I Expression and Transcription Factor CBFa1 on Bone Cells by GlucocorticoidJournal of Biological Chemistry, 1998
- Dexamethasone Enhancement of Betaglycan (TGF-β Type III Receptor) Gene Expression in Osteoblast-like CellsExperimental Cell Research, 1994
- Periodontal therapy by local delivery of tetracyclineJournal of Clinical Periodontology, 1979